Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.92% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-14
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.92%, a 3.21% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.05%, a 5.74% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.83%, a 12.65% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-03-31 was 3.40%, a 122.22% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.90%, a 1.27% decline from fiscal 2024.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.95%, a 16.18% increase from fiscal 2023.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.40%, a 122.22% increase from fiscal 2022.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.53%, a 150.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 3.92% 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 3.92% 10-Q · filed 2026-05-14 | |||||
| 2025-12-31 | 3.90% 10-K · filed 2026-03-16 | |||||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 4.05% 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | 4.05% 10-Q · filed 2026-05-14 | |||||
| 2024-12-31 | 3.95% 10-K · filed 2026-03-16 | |||||
| 2024-09-30 | 3.83% 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 3.83% 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | 3.83% 10-Q · filed 2025-05-12 | |||||
| 2023-12-31 | 3.40% 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | 3.40% 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | 3.40% 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | 3.40% 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | 1.53% 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | 1.53% 10-Q · filed 2023-11-03 | |||||
| 2022-06-30 | 1.53% 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | 1.53% 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 0.61% 10-K · filed 2023-03-21 | |||||
| 2021-09-30 | 0.61% 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 0.61% 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 0.61% 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 0.38% 10-K · filed 2022-03-16 | 1.75% 10-K · filed 2021-03-09 | ||||
| 2020-09-30 | 0.54% 10-Q · filed 2021-11-09 | 0.38% 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | 0.54% 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | 1.00% 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 2.43% 10-K · filed 2021-03-09 | 1.75% 10-K · filed 2020-03-12 | ||||
| 2019-09-30 | 1.76% 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | 1.94% 10-Q · filed 2020-08-07 | |||||
| 2019-03-31 | 2.49% 10-Q · filed 2019-05-08 | |||||
| 2018-12-31 | 2.43% 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | 2.43% 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | 2.43% 10-Q · filed 2018-08-13 | |||||
| 2018-03-31 | 2.43% 10-Q · filed 2018-05-14 | |||||
| 2017-12-31 | 1.71% 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |